OSCR
Oscar Health, Inc.
OSCR has the edge over PHG overall, supported by stronger fundamentals and stronger modeled upside.
PHG
Koninklijke Philips N.V.
PHG has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PHG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Healthy |
PHG's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over PHG in the historical PE scenario, which offers more potential upside but is not a forecast.
PHG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7x | $9.06 | -70% |
| Current | 23x | $30.05 | — |
| Fair | 29x | $37.91 | +26% |
| Expensive | 40x | $51.41 | +71% |
Historical ranges are pointers, not guarantees.
PHG's PE is 23x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PHG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for PHG, with profitability improving.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
PHG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $1.29 | +579% |
| Q1 2026 | $1.12 | +155% |
| Q4 2025 | $1.03 | +$1.90 |
| Q3 2025 | $0.18 | +$0.61 |
| Q2 2025 | $0.19 | +$0.73 |
| Q1 2025 | $0.44 | +$1.43 |
| Q1 2024 | -$0.99 | +$1.60 |
| Q1 2023 | -$2.59 | -171% |
PHG has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PHG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
PHG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.8B | +0.5% |
| Q1 2026 | $4.3B | -4.7% |
| Q4 2025 | $5.7B | +1.1% |
| Q3 2025 | $4.8B | -1.7% |
| Q2 2025 | $4.8B | -2.8% |
| Q1 2025 | $4.6B | -1% |
| Q4 2024 | $5.6B | -0.4% |
| Q3 2024 | $4.9B | -2.1% |
PHG's revenue fell from its 2020 peak and has held roughly level since: $4.8B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 14% | +4.8 points |
| Q1 2026 | 6.2% | +2.4 points |
| Q4 2025 | 11% | +6.6 points |
| Q3 2025 | 7.7% | 0 points |
| Q2 2025 | 9.2% | -9.1 points |
| Q1 2025 | 3.8% | +24 points |
| Q4 2024 | 4% | +3.5 points |
| Q3 2024 | 7.7% | +2.7 points |
PHG has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over PHG on cash flow, with more consistent year-over-year improvement.
PHG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $243.3M | -3.9% |
| Q1 2026 | $129.9M | +$1.3B |
| Q4 2025 | $1.5B | +$1.5B |
| Q3 2025 | $287.7M | +$287.7M |
| Q2 2025 | $253.3M | +$331M |
| Q1 2025 | -$1.2B | -$776.3M |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
PHG's free cash flow is usually positive and has bounced back after one negative quarter: $2.1B over the past year, against −$902M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PHG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +44K shares |
| 1 year | +1.2% | +11.9M shares |
| 3 years | +2.3% | +22M shares |
| 5 years | +1.3% | +12.3M shares |
| Available history | +0.6% | +6.2M shares |
PHG has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $75.5M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
PHG spent $76M buying back its own shares over the past year, after none the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over PHG on leverage, with a lower net debt burden relative to earnings.
PHG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.9x | Healthy |
| Q1 2026 | 2.0x | Moderate |
| Q4 2025 | 2.0x | Moderate |
| Q3 2025 | 3.0x | Moderate |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 3.5x | Elevated |
| Q4 2024 | 6.2x | High |
| Q3 2024 | -1.5x | Net Cash |
PHG's net debt is about 1.9 years of its operating earnings (EBITDA), down from 3.5 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PHG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.3 | Neutral |
| Stochastic | 84.8 | Overbought |
PHG's weekly RSI is 64 (neutral) and its Stochastic is 85 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over PHG on valuation relative to its sector.
PHG PE vs Healthcare Sector
| Metric | PHG | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 9.8% below |
| PE % | 29 | 29 | Same percentile |
PHG is trading at 23x earnings, in line with the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
PHG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.6 | 13% above |
| 20 week MA | $26.6 | 13% above |
| 50 week MA | $27.4 | 9.9% above |
| 100 week MA | $26.7 | 13% above |
| 200 week MA | $24.5 | 23% above |
PHG is in an uptrend: it's above all five of its weekly moving averages, and 23% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PHG on returns for 2026, with the stronger performance.
PHG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.5 | $49.8 | +12% |
| 2021 | $49.8 | $33.6 | -33% |
| 2022 | $33.6 | $14.9 | -56% |
| 2023 | $14.9 | $22.6 | +51% |
| 2024 | $22.6 | $25.6 | +13% |
| 2025 | $25.6 | $27.1 | +6% |
| 2026 YTD | $27.1 | $30.1 | +11% |
PHG has finished higher in four of the last six years. It's up 11% so far in 2026.